Highly developable soluble T cell receptors (TCRs) with high target affinities discovered from large yeast libraries

Engineered anti-CD3 and anti-CD28 antibodies with potent T cell activation and strong developability.

Data-driven yeast platform delivers potent, peptide-specific TCRs ready for therapeutic development.

Adimab’s yeast-based platform accelerates antibody programs from discovery to clinic

Yeast-based engineering yields high-affinity soluble TCRs, enabling potent, precise T cell therapeutics

Masked anti-CD3 antibodies activate selectively in tumors, offering potent, localized T-cell engagement